Hospital
Lakeland Hospitals at Niles and ST Joseph, INC
Lakeland Hospitals at Niles and ST Joseph, INC was paid $78.22M by Medicaid between Jan 2018 and Dec 2024, across 576 billing codes. Its largest line is 99284, emergency room visit (serious) — 13% of everything it billed.
33Billing provider infoLAKELAND HOSPITALS AT NILES AND ST JOSEPH, INC
SAINT JOSEPH, MI 49085
SAINT JOSEPH, MI 49085
33aNPI1134220031assigned 09/26/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$78.22M
24GClaims2,391,298
24DCodes billed576
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Michigan
Rank by total paid#13 of 86
Median peer was paid$21.55M
This provider vs. median3.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official COX, MATTHEW controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 316,020 | $9.24M | |
| 2019 | 302,884 | $9.26M | |
| 2020 | 298,027 | $9.20M | |
| 2021 | 382,972 | $12.61M | |
| 2022 | 369,818 | $12.57M | |
| 2023 | 401,568 | $14.00M | |
| 2024incomplete | 320,009 | $11.34M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 53,510 | 47,387 | $10.52M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 13% | 31,763 | 28,528 | $9.96M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 75,907 | 70,591 | $9.42M |
| G0378 | Hospital observation service, per hour | 9.3% | 21,497 | 13,480 | $7.24M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.7% | 38,365 | 32,200 | $3.64M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.3% | 79,159 | 25,121 | $1.83M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.0% | 26,135 | 20,778 | $1.59M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.8% | 10,079 | 9,799 | $1.45M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.7% | 15,197 | 11,115 | $1.35M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.5% | 11,366 | 8,150 | $1.18M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.5% | 6,845 | 4,449 | $1.14M |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.2% | 33,022 | 25,368 | $941K |
564 more codes
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.2% | 13,113 | $931K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.1% | 27,092 | $898K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.1% | 1,755 | $890K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.1% | 3,377 | $841K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 276 | $775K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 19,823 | $761K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 31,002 | $677K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 12,560 | $651K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 8,443 | $605K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 1,180 | $602K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,747 | $573K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 5,823 | $566K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 6,811 | $547K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 8,290 | $523K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 11,796 | $484K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 29,736 | $439K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 2,105 | $407K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 861 | $394K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 16,245 | $387K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 7,809 | $381K |
| 71045 | Radiologic examination, chest; single view | <1% | 9,497 | $329K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 5,449 | $325K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 943 | $319K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,368 | $318K |
| 93975 | <1% | 2,481 | $301K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 20,208 | $296K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 20,189 | $293K |
| 15275 | <1% | 312 | $289K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 5,660 | $283K |
| 76830 | Ultrasound, transvaginal | <1% | 4,822 | $280K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 7,126 | $280K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,476 | $275K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 567 | $271K |
| 97162 | <1% | 5,573 | $265K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 4,698 | $265K |
| 80061 | Lipid panel | <1% | 23,781 | $262K |
| 97161 | <1% | 5,431 | $257K | |
| 76801 | <1% | 4,407 | $257K | |
| 80053 | Comprehensive metabolic panel | <1% | 114,637 | $234K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,127 | $230K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 4,498 | $229K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 4,529 | $228K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 5,193 | $216K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 3,425 | $210K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,500 | $206K |
| 86900 | <1% | 7,197 | $204K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 1,672 | $202K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 29,134 | $199K |
| 36415 | Collection of venous blood by venipuncture | <1% | 163,904 | $178K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 2,171 | $169K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 3,734 | $167K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,636 | $166K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 112,611 | $163K |
| 93458 | <1% | 272 | $150K | |
| 76770 | <1% | 2,611 | $148K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 9,872 | $138K |
| 96367 | <1% | 4,198 | $137K | |
| 94060 | <1% | 1,389 | $132K | |
| 97597 | <1% | 1,378 | $128K | |
| 93971 | <1% | 2,287 | $128K | |
| 96415 | <1% | 2,610 | $127K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 8,103 | $126K |
| 47562 | <1% | 55 | $123K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 1,455 | $118K |
| 87507 | <1% | 697 | $112K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 15,926 | $110K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 1,776 | $108K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 33,957 | $107K |
| 10060 | <1% | 1,139 | $104K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 23,273 | $95K |
| 72141 | <1% | 625 | $89K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 36,061 | $88K |
| S4005 | Interim labor facility global (labor occurring but not resulting in delivery) | <1% | 775 | $85K |
| 92523 | <1% | 1,086 | $85K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 8,609 | $84K |
| 97165 | <1% | 1,818 | $83K | |
| 92526 | <1% | 1,810 | $82K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,296 | $81K |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 892 | $81K |
| 72110 | <1% | 2,549 | $81K | |
| 76642 | <1% | 2,051 | $80K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 2,444 | $77K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 19,358 | $77K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 4,449 | $75K |
| 88142 | <1% | 6,543 | $75K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 96 | $73K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 1,247 | $72K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,286 | $72K |
| 59025 | Fetal non-stress test | <1% | 743 | $70K |
| J9271 | Injection, pembrolizumab, 1 mg | <1% | 15 | $69K |
| 76536 | <1% | 1,366 | $68K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 862 | $68K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 3,224 | $63K |
| 71271 | <1% | 1,206 | $63K | |
| 71250 | <1% | 1,008 | $62K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 635 | $59K |
| 70491 | <1% | 528 | $58K | |
| 86850 | <1% | 8,450 | $57K | |
| 73562 | <1% | 1,922 | $57K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 8,628 | $55K |
| 96417 | <1% | 1,330 | $54K | |
| 73030 | <1% | 4,054 | $53K | |
| 73221 | <1% | 424 | $51K | |
| 86480 | <1% | 1,617 | $50K | |
| 97166 | <1% | 1,454 | $49K | |
| 85027 | <1% | 21,663 | $49K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 3,016 | $48K |
| 70496 | <1% | 1,152 | $46K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,585 | $46K |
| 87088 | <1% | 25,386 | $45K | |
| 86780 | <1% | 6,069 | $45K | |
| 83970 | <1% | 2,337 | $44K | |
| 73630 | <1% | 4,605 | $42K | |
| 95811 | <1% | 81 | $41K | |
| 72100 | <1% | 1,723 | $41K | |
| 77066 | Tomosynthesis, mammo | <1% | 697 | $41K |
| 82728 | <1% | 7,070 | $37K | |
| 96523 | <1% | 1,588 | $37K | |
| 82607 | <1% | 6,240 | $37K | |
| 73130 | <1% | 4,192 | $36K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 2,947 | $36K |
| 97116 | <1% | 3,087 | $36K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 3,207 | $36K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 19,745 | $34K |
| 93017 | <1% | 1,462 | $34K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,421 | $32K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 4,908 | $32K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 14,673 | $31K |
| 73110 | <1% | 2,835 | $31K | |
| 93308 | <1% | 532 | $31K | |
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | <1% | 16 | $30K |
| 84439 | <1% | 7,472 | $30K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 525 | $30K |
| 73502 | <1% | 2,137 | $30K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 1,450 | $29K |
| 74018 | <1% | 1,835 | $29K | |
| 73610 | <1% | 3,981 | $28K | |
| 70486 | <1% | 766 | $27K | |
| 36430 | <1% | 178 | $26K | |
| 73564 | <1% | 3,804 | $25K | |
| 80074 | <1% | 1,360 | $25K | |
| 87536 | <1% | 536 | $25K | |
| 72040 | <1% | 1,312 | $25K | |
| 77065 | Tomosynthesis, mammo | <1% | 723 | $25K |
| 93000 | <1% | 2,839 | $24K | |
| 87340 | <1% | 6,601 | $24K | |
| 87077 | <1% | 8,936 | $23K | |
| 93970 | <1% | 217 | $23K | |
| 97163 | <1% | 419 | $22K | |
| 99205 | Prolong outpt/office vis | <1% | 211 | $22K |
| 86803 | <1% | 4,270 | $22K | |
| 99254 | <1% | 261 | $22K | |
| 83550 | <1% | 6,928 | $22K | |
| 93798 | <1% | 335 | $22K | |
| 29580 | <1% | 240 | $22K | |
| 82947 | <1% | 1,588 | $21K | |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 52 | $21K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 260 | $21K |
| 87186 | <1% | 8,766 | $20K | |
| 72156 | <1% | 127 | $20K | |
| 87905 | <1% | 10,070 | $19K | |
| 84153 | <1% | 2,190 | $19K | |
| 87808 | <1% | 9,453 | $19K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 62 | $19K |
| 93015 | <1% | 725 | $19K | |
| 85610 | <1% | 15,844 | $19K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 673 | $19K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 378 | $18K |
| 82043 | <1% | 5,865 | $18K | |
| 84702 | <1% | 14,867 | $17K | |
| 83540 | <1% | 7,093 | $17K | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 678 | $17K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,813 | $16K |
| 72050 | <1% | 386 | $16K | |
| 77336 | <1% | 223 | $15K | |
| 99243 | <1% | 237 | $15K | |
| 99223 | Prolong inpt eval add15 m | <1% | 161 | $15K |
| 86140 | <1% | 8,114 | $15K | |
| 84403 | <1% | 1,085 | $14K | |
| 82746 | <1% | 2,304 | $14K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 218 | $13K |
| 93016 | <1% | 1,078 | $13K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 35,473 | $13K |
| 73140 | <1% | 1,909 | $13K | |
| 72072 | <1% | 534 | $13K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 5,398 | $13K |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 361 | $13K |
| 93018 | <1% | 1,533 | $13K | |
| 83880 | <1% | 3,363 | $12K | |
| 86360 | <1% | 474 | $12K | |
| 76870 | <1% | 784 | $12K | |
| 80076 | <1% | 2,912 | $12K | |
| 72158 | <1% | 125 | $12K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,057 | $11K |
| 93880 | <1% | 110 | $11K | |
| 86762 | <1% | 2,979 | $11K | |
| 83735 | <1% | 21,889 | $11K | |
| 81001 | <1% | 50,589 | $11K | |
| 74183 | <1% | 66 | $11K | |
| 88307 | <1% | 594 | $11K | |
| 73080 | <1% | 1,522 | $11K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 100 | $11K |
| 97035 | <1% | 1,790 | $11K | |
| 86038 | <1% | 2,065 | $11K | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 816 | $10K |
| 86300 | <1% | 1,576 | $10K | |
| 82784 | <1% | 1,696 | $10K | |
| 0012A | <1% | 332 | $10K | |
| 87390 | <1% | 1,006 | $10K | |
| 86359 | <1% | 474 | $10K | |
| 87081 | <1% | 3,184 | $10K | |
| 84207 | <1% | 714 | $10K | |
| 86003 | <1% | 245 | $10K | |
| 84481 | <1% | 1,025 | $8K | |
| 80306 | <1% | 2,729 | $8K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 299 | $8K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,304 | $8K |
| 81511 | <1% | 538 | $8K | |
| 82950 | <1% | 3,007 | $8K | |
| 85652 | <1% | 7,637 | $8K | |
| 29515 | <1% | 99 | $8K | |
| 83001 | <1% | 818 | $8K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 30 | $7K |
| 85576 | <1% | 471 | $7K | |
| 88304 | <1% | 2,037 | $7K | |
| 95806 | <1% | 88 | $7K | |
| 83921 | <1% | 690 | $7K | |
| 93296 | <1% | 529 | $7K | |
| 86702 | <1% | 1,006 | $7K | |
| 84146 | <1% | 729 | $7K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 672 | $7K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 25 | $7K |
| 97012 | <1% | 1,052 | $7K | |
| 88342 | <1% | 437 | $7K | |
| 84425 | <1% | 650 | $7K | |
| 99152 | <1% | 2,270 | $7K | |
| 0011A | <1% | 340 | $7K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 618 | $6K |
| 77080 | <1% | 103 | $6K | |
| 87070 | <1% | 2,723 | $6K | |
| 80050 | General health panel | <1% | 226 | $6K |
| 82570 | <1% | 3,386 | $6K | |
| 93925 | <1% | 66 | $6K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 8,124 | $6K |
| 73590 | <1% | 999 | $6K | |
| 86376 | <1% | 981 | $6K | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 495 | $5K |
| 93922 | <1% | 172 | $5K | |
| 43235 | <1% | 13 | $5K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 89 | $5K |
| 83655 | <1% | 814 | $5K | |
| 90675 | <1% | 35 | $5K | |
| 96411 | <1% | 140 | $5K | |
| 70498 | <1% | 1,147 | $5K | |
| 74240 | <1% | 53 | $5K | |
| 83516 | <1% | 584 | $5K | |
| 86701 | <1% | 1,040 | $5K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 1,158 | $5K |
| 80069 | <1% | 1,125 | $4K | |
| 93295 | <1% | 208 | $4K | |
| 87102 | <1% | 1,025 | $4K | |
| 97802 | <1% | 291 | $4K | |
| 94726 | <1% | 1,130 | $4K | |
| 85730 | <1% | 7,346 | $4K | |
| 87653 | <1% | 269 | $4K | |
| 73700 | <1% | 68 | $4K | |
| 80164 | <1% | 955 | $4K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 341 | $4K |
| 86706 | <1% | 916 | $4K | |
| 97014 | <1% | 484 | $4K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 14 | $4K |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 196 | $4K |
| 93298 | <1% | 172 | $4K | |
| 0031A | <1% | 101 | $4K | |
| 96416 | <1% | 19 | $4K | |
| 73090 | <1% | 826 | $4K | |
| 93793 | <1% | 1,622 | $4K | |
| 83690 | <1% | 25,249 | $3K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 14 | $3K |
| 72146 | <1% | 25 | $3K | |
| 84156 | <1% | 2,803 | $3K | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 1,680 | $3K |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 183 | $3K |
| 86431 | <1% | 1,384 | $3K | |
| 82378 | <1% | 834 | $3K | |
| 86235 | <1% | 157 | $3K | |
| 83002 | <1% | 309 | $3K | |
| 82550 | <1% | 2,216 | $3K | |
| 84550 | <1% | 1,862 | $3K | |
| 94729 | <1% | 1,228 | $3K | |
| 97763 | <1% | 70 | $3K | |
| 84402 | <1% | 214 | $3K | |
| 93248 | <1% | 164 | $2K | |
| 86161 | <1% | 228 | $2K | |
| 29581 | <1% | 29 | $2K | |
| 0001A | <1% | 72 | $2K | |
| 97760 | <1% | 89 | $2K | |
| 87206 | <1% | 1,755 | $2K | |
| 83615 | <1% | 2,279 | $2K | |
| 73560 | <1% | 103 | $2K | |
| 82670 | <1% | 148 | $2K | |
| 86364 | <1% | 327 | $2K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 116 | $2K |
| 84100 | <1% | 1,424 | $2K | |
| 95819 | <1% | 30 | $2K | |
| 82247 | <1% | 778 | $2K | |
| 71101 | <1% | 335 | $2K | |
| 84630 | <1% | 311 | $2K | |
| 99406 | <1% | 230 | $2K | |
| 87522 | Neg quan hep c or qual rna | <1% | 93 | $2K |
| 82533 | <1% | 233 | $2K | |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 12 | $2K |
| 93246 | <1% | 162 | $2K | |
| 82525 | <1% | 282 | $2K | |
| 80329 | <1% | 45 | $2K | |
| 82951 | <1% | 218 | $2K | |
| 72157 | <1% | 24 | $1K | |
| 99255 | <1% | 14 | $1K | |
| 85055 | <1% | 146 | $1K | |
| 93351 | <1% | 12 | $1K | |
| 74022 | <1% | 239 | $1K | |
| 0002A | <1% | 36 | $1K | |
| 86225 | <1% | 218 | $1K | |
| 97803 | <1% | 135 | $1K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 16 | $1K |
| 81025 | <1% | 21,895 | $1K | |
| 86200 | <1% | 294 | $1K | |
| 86618 | <1% | 188 | $1K | |
| 84484 | <1% | 18,875 | $1K | |
| 85379 | <1% | 4,514 | $923.60 | |
| 87631 | <1% | 414 | $918.26 | |
| 87338 | <1% | 116 | $914.43 | |
| 00811 | <1% | 14 | $900.42 | |
| 85045 | <1% | 1,325 | $897.23 | |
| 99442 | <1% | 58 | $892.99 | |
| 72082 | <1% | 13 | $845.65 | |
| 86665 | <1% | 51 | $841.01 | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 49 | $811.80 |
| 87563 | <1% | 45 | $805.98 | |
| 93325 | <1% | 459 | $796.17 | |
| 87040 | <1% | 5,506 | $794.88 | |
| 73660 | <1% | 90 | $791.01 | |
| 82024 | <1% | 43 | $739.27 | |
| 80177 | <1% | 671 | $736.73 | |
| 0064A | <1% | 20 | $721.04 | |
| 86769 | <1% | 31 | $705.84 | |
| 86160 | <1% | 64 | $679.32 | |
| 82785 | <1% | 92 | $663.39 | |
| 86147 | <1% | 29 | $638.38 | |
| 87529 | <1% | 40 | $628.74 | |
| 93272 | <1% | 43 | $602.84 | |
| 90686 | <1% | 68 | $585.62 | |
| 99221 | <1% | 13 | $576.40 | |
| 84145 | <1% | 1,772 | $560.37 | |
| 76000 | <1% | 192 | $552.94 | |
| 84446 | <1% | 72 | $548.56 | |
| 86308 | <1% | 499 | $533.77 | |
| 72170 | <1% | 25 | $519.77 | |
| 0004A | <1% | 14 | $506.07 | |
| 12001 | <1% | 1,671 | $505.97 | |
| 92610 | <1% | 13 | $500.47 | |
| 94618 | <1% | 49 | $479.28 | |
| 84590 | <1% | 75 | $462.86 | |
| 84681 | <1% | 42 | $459.06 | |
| 76376 | <1% | 220 | $438.32 | |
| 82330 | <1% | 376 | $437.04 | |
| 82977 | <1% | 122 | $435.58 | |
| 86592 | <1% | 169 | $384.53 | |
| 84165 | <1% | 88 | $380.56 | |
| 93227 | <1% | 25 | $372.09 | |
| 94762 | <1% | 67 | $354.49 | |
| 82274 | <1% | 43 | $350.24 | |
| 85014 | <1% | 1,308 | $348.77 | |
| 85018 | <1% | 1,099 | $347.01 | |
| 73060 | <1% | 79 | $340.05 | |
| 82248 | <1% | 144 | $335.50 | |
| 82627 | <1% | 31 | $331.44 | |
| 73521 | <1% | 12 | $330.68 | |
| 84112 | <1% | 120 | $322.02 | |
| 83605 | <1% | 7,171 | $314.71 | |
| 12011 | <1% | 609 | $305.04 | |
| 73070 | <1% | 15 | $285.89 | |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | <1% | 1,075 | $285.59 |
| 0240U | <1% | 298 | $285.26 | |
| 86704 | <1% | 56 | $276.46 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 467 | $275.11 |
| 99443 | <1% | 12 | $270.96 | |
| 94010 | <1% | 38 | $255.43 | |
| 86800 | <1% | 37 | $245.90 | |
| 87210 | <1% | 813 | $242.83 | |
| 96401 | <1% | 24 | $242.32 | |
| 83993 | <1% | 24 | $231.43 | |
| 87205 | <1% | 222 | $226.98 | |
| G0008 | Administration of influenza virus vaccine | <1% | 68 | $214.22 |
| 76937 | <1% | 669 | $211.76 | |
| 82952 | <1% | 106 | $208.51 | |
| 93321 | <1% | 64 | $208.42 | |
| 86708 | <1% | 27 | $188.62 | |
| 93242 | <1% | 14 | $180.45 | |
| 93244 | <1% | 13 | $179.36 | |
| 86255 | <1% | 25 | $169.20 | |
| 93356 | <1% | 40 | $166.71 | |
| 82565 | <1% | 105 | $157.76 | |
| 82010 | <1% | 2,064 | $155.09 | |
| 87641 | <1% | 43 | $138.96 | |
| 80197 | <1% | 19 | $136.68 | |
| 99441 | <1% | 17 | $134.64 | |
| 82553 | <1% | 28 | $121.52 | |
| 86304 | <1% | 14 | $117.72 | |
| 86696 | <1% | 13 | $108.00 | |
| 82731 | <1% | 13 | $106.40 | |
| 83520 | <1% | 57 | $103.95 | |
| 85007 | <1% | 200 | $99.84 | |
| 84132 | <1% | 369 | $99.12 | |
| 73552 | <1% | 47 | $96.47 | |
| 82140 | <1% | 33 | $95.60 | |
| 86664 | <1% | 14 | $94.71 | |
| 90715 | <1% | 2,887 | $91.86 | |
| 85046 | <1% | 60 | $84.79 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 36,327 | $78.88 |
| 86735 | <1% | 12 | $73.80 | |
| 82105 | <1% | 12 | $73.36 | |
| 86765 | <1% | 12 | $72.81 | |
| 96376 | <1% | 12,367 | $68.23 | |
| 86695 | <1% | 13 | $66.24 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 32,218 | $52.02 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 8,349 | $50.20 |
| 82150 | <1% | 14 | $48.84 | |
| 82803 | <1% | 732 | $39.76 | |
| 81003 | <1% | 593 | $39.36 | |
| 94664 | <1% | 1,811 | $36.75 | |
| 85660 | <1% | 12 | $34.10 | |
| 29125 | <1% | 853 | $33.39 | |
| 80178 | <1% | 14 | $29.52 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 13,136 | $27.71 |
| 86901 | <1% | 6,543 | $20.50 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 9,848 | $18.46 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 8,349 | $18.13 |
| 84480 | <1% | 24 | $17.82 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 2,863 | $14.68 |
| 86787 | <1% | 15 | $14.10 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 4,021 | $12.24 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 11,866 | $11.94 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 6,270 | $11.92 |
| 84295 | <1% | 155 | $11.26 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 4,596 | $11.16 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 19,525 | $10.89 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 8,547 | $10.67 |
| 87075 | <1% | 15 | $10.18 | |
| 82077 | <1% | 579 | $9.45 | |
| A9270 | Non-covered item or service | <1% | 4,650 | $7.70 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 322 | $7.40 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 9,706 | $5.05 |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 7,371 | $3.90 |
| 91303 | <1% | 65 | $1.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 3,046 | $0.62 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 4,070 | $0.26 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 20 | $0.24 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 4,857 | $0.20 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 3,084 | $0.06 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 2,528 | $0.01 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 1,176 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 1,234 | $0.00 |
| J3490 | Unclassified drugs | 0% | 3,140 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 1,191 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 2,287 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 1,505 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 86 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 2,450 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 2,628 | $0.00 |
| C1769 | Guide wire | 0% | 1,355 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 1,442 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 904 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 930 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 4,550 | $0.00 |
| 12002 | 0% | 640 | $0.00 | |
| J7999 | Compounded drug, not otherwise classified | 0% | 840 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 3,206 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 160 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 611 | $0.00 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 302 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 1,677 | $0.00 |
| 76377 | 0% | 362 | $0.00 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 201 | $0.00 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 888 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 4,808 | $0.00 |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 280 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 1,057 | $0.00 |
| 80051 | 0% | 29 | $0.00 | |
| 95886 | 0% | 12 | $0.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 205 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 13 | $0.00 |
| 74420 | 0% | 29 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 416 | $0.00 |
| 99024 | 0% | 144 | $0.00 | |
| 88300 | 0% | 162 | $0.00 | |
| 36416 | 0% | 269 | $0.00 | |
| A9573 | Injection, gadopiclenol, 1 ml | 0% | 383 | $0.00 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 210 | $0.00 |
| 91301 | 0% | 684 | $0.00 | |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 78 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 13 | $0.00 |
| 96368 | 0% | 90 | $0.00 | |
| 88341 | 0% | 13 | $0.00 | |
| 97010 | 0% | 360 | $0.00 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | 0% | 33 | $0.00 |
| 29130 | 0% | 65 | $0.00 | |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 43 | $0.00 |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 17 | $0.00 |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | 0% | 82 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 13 | $0.00 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 39 | $0.00 |
| C1726 | Catheter, balloon dilatation, non-vascular | 0% | 12 | $0.00 |
| 80320 | 0% | 59 | $0.00 | |
| 91306 | 0% | 19 | $0.00 | |
| C1781 | Mesh (implantable) | 0% | 15 | $0.00 |
| Q4196 | Puraply am, per square centimeter (add-on, list separately in addition to primary procedure) | 0% | 137 | $0.00 |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | 0% | 16 | $0.00 |
| J9045 | Injection, carboplatin, 50 mg | 0% | 17 | $0.00 |
| 30140 | 0% | 15 | $0.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 11,168 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 2,068 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 991 | $0.00 |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | 0% | 1,985 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 3,147 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 2,041 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 1,588 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 4,817 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 785 | $0.00 |
| 91300 | 0% | 189 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 213 | $0.00 |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 1,143 | $0.00 |
| 76942 | 0% | 107 | $0.00 | |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 147 | $0.00 |
| C1758 | Catheter, ureteral | 0% | 90 | $0.00 |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | 0% | 84 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 122 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 1,696 | $0.00 |
| J2800 | Injection, methocarbamol, up to 10 ml | 0% | 87 | $0.00 |
| J9190 | Injection, fluorouracil, 500 mg | 0% | 151 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 319 | $0.00 |
| 86922 | 0% | 43 | $0.00 | |
| 0722T | 0% | 12 | $0.00 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 52 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 195 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 253 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 53 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 62 | $0.00 |
| 1124F | 0% | 256 | $0.00 | |
| 80143 | 0% | 351 | $0.00 | |
| 89051 | 0% | 18 | $0.00 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 56 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 81 | $0.00 |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | 0% | 51 | $0.00 |
| 0097U | 0% | 26 | $0.00 | |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | 0% | 17 | $0.00 |
| 80179 | 0% | 347 | $0.00 | |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | 0% | 14 | $0.00 |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | 0% | 17 | $0.00 |
| J0640 | Injection, leucovorin calcium, per 50 mg | 0% | 65 | $0.00 |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 0% | 13 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 315 | $0.00 |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | 0% | 27 | $0.00 |
| J7070 | Infusion, d5w, 1000 cc | 0% | 63 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCOX, MATTHEW (CFO)
| Provider | Location | Paid |
|---|---|---|
| Spectrum Health Hospitals | Grand Rapids, MI | $243.22M |
| Oakwood Healthcare, INC. | Dearborn, MI | $165.61M |
| William Beaumont Hospital | Royal Oak, MI | $162.64M |
| William Beaumont Hospital | Troy, MI | $84.88M |
| Botsford General Hospital | Farmington Hills, MI | $72.21M |
| William Beaumont Hospital | Grosse Pointe, MI | $61.49M |
| Oakwood Healthcare, INC. | Wayne, MI | $55.44M |
| Oakwood Healthcare, INC. | Taylor, MI | $50.28M |
| Oakwood Healthcare, INC. | Trenton, MI | $23.26M |
| Spectrum Health United | Greenville, MI | $20.99M |
| Mecosta County Medical Center | Big Rapids, MI | $19.50M |
| Pennock Hospital | Hastings, MI | $15.24M |
| Reed City Hospital Corporation | Reed City, MI | $15.02M |
| Zeeland Community Hospital | Zeeland, MI | $10.12M |
| Lakeland Community Hospital Watervliet | Watervliet, MI | $9.85M |
| Lakeland Community Hospital Watervliet | Niles, MI | $9.05M |
| Visiting Nurse Services of Western Michigan | Grand Rapids, MI | $4.54M |
| Lakeland Hospitals at Niles and ST Joseph, INC | Benton Harbor, MI | $3.33M |
| Banner Mesa Surgery Center LLC | Mesa, AZ | $2.80M |
| Lakeland Community Hospital Watervliet | Watervliet, MI | $2.55M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.